29.10.2014 • NewsClariantMAMergers & Acquisitions (M&A)

Clariant divests its Energy Storage Business to Johnson Matthey

Clariant has agreed to divest its Business Line Energy Storage to Johnson Matthey. The total consideration of the sale amounts to $75 million at closing which is expected early 2015.

The Energy Storage business of Clariant is the largest hydrothermal Lithium Iron Phosphate (LFP) producer in the world. The lithium ion cathode material is used in electric vehicles and stationary battery applications. In 2013 the Energy Storage business generated around CHF 16 million in sales. The business employs around 100 employees predominantly in Canada and Germany.

"The divestment of the Energy Storage business with its LFP technology is part of our focused portfolio management and reallocating capital towards our core areas Care Chemicals, Catalysis and Energy, Natural Resources, and Plastics and Coatings," said Hariolf Kottmann, CEO of Clariant.

Robert MacLeod, Chief Executive of Johnson Matthey said: "This acquisition provides us with a strong position in LFP from which to develop a broad portfolio of battery materials. It further strengthens our battery technologies capability which marks an important step in Johnson Matthey's long term strategy to establish new business areas."

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.